The local medical sector is buzzing with the introduction of retatrutide, a innovative dual GIP and GLP-1 receptor agonist showing remarkable results in early trials for addressing obesity. This therapy https://thefairlist.com/story12029092/retatrutide-australia-a-emerging-hope-for-weight-management